Attenuation of allergic airway inflammation and associated pulmonary functions by mycobacterial antigens is independent of IgE in a mouse model of asthma

Michael T. Hopfenspirger, Sharidan K. Parr, Robert G. Townley, Devendra K. Agrawal

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Since the observation that Bacillus Calmette-Guérin (BCG) vaccination in children correlates with a decreased prevalence of asthma, several investigators have been attempting to reproduce this effect experimentally in mouse models of asthma. While these reports have agreed in some areas, uncertainty has remained as to the effect of BCG on IgE and asthmatic response in general. Furthermore, the effect of mycobacterial antigens on the early allergic response and the release of bronchoconstrictory mediators have not been examined. In the present study, we have aimed to more completely describe the effect of BCG and Mycobacterium vaccae on early and late allergic responses (EAR and LAR, respectively), airway hyperresponsiveness (AHR) and broncho-constrictory mediators in the mouse model of allergic airway inflammation. Methods: Using BALB/c mice sensitized to ovalbumin (OVA) and treated twice with either BCG or M. vaccae (1 x 105 CFU, intranasally), we investigated airway resistance of both the EAR and LAR, AHR to methacholine, serum total and antigen-specific IgE, cysteinyl leukotrienes in bronchoalveolar lavage (BAL) fluid (10 min following challenge), a complete cell differential of the BAL (24 h post-challenge), BAL and serum cytokines and lung histology. Results: Neither BCG nor M. vaccae were able to attenuate the EAR, yet both were able to abrogate the parameters used to evaluate the LAR. Interestingly, in neither case were serum or OVA-specific IgE levels reduced after treatment with mycobacterial antigens and type 1/type 2 T cell cytokine skewing, based on cytokine levels in BAL and serum, was incomplete. Conclusions: These results have led us to conclude that the mycobacterial antigens elicit potential anti-asthmatic effects independent of changes in IgE levels. We speculate that mycobacteria likely directly or indirectly suppress eosinophil effector function via attenuation of type 2 T cell-mediated immune responses.

Original languageEnglish
Pages (from-to)21-32
Number of pages12
JournalAllergology International
Volume51
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Bacillus
Immunoglobulin E
Pneumonia
Asthma
Antigens
Bronchoalveolar Lavage
Ovalbumin
Mycobacterium
Cytokines
Serum
Anti-Asthmatic Agents
T-Lymphocytes
Airway Resistance
Methacholine Chloride
Bronchoalveolar Lavage Fluid
Eosinophils
Uncertainty
Histology
Vaccination
Research Personnel

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Attenuation of allergic airway inflammation and associated pulmonary functions by mycobacterial antigens is independent of IgE in a mouse model of asthma. / Hopfenspirger, Michael T.; Parr, Sharidan K.; Townley, Robert G.; Agrawal, Devendra K.

In: Allergology International, Vol. 51, No. 1, 2002, p. 21-32.

Research output: Contribution to journalArticle

@article{55c15e3ce0bf47de9be46579c49345e3,
title = "Attenuation of allergic airway inflammation and associated pulmonary functions by mycobacterial antigens is independent of IgE in a mouse model of asthma",
abstract = "Background: Since the observation that Bacillus Calmette-Gu{\'e}rin (BCG) vaccination in children correlates with a decreased prevalence of asthma, several investigators have been attempting to reproduce this effect experimentally in mouse models of asthma. While these reports have agreed in some areas, uncertainty has remained as to the effect of BCG on IgE and asthmatic response in general. Furthermore, the effect of mycobacterial antigens on the early allergic response and the release of bronchoconstrictory mediators have not been examined. In the present study, we have aimed to more completely describe the effect of BCG and Mycobacterium vaccae on early and late allergic responses (EAR and LAR, respectively), airway hyperresponsiveness (AHR) and broncho-constrictory mediators in the mouse model of allergic airway inflammation. Methods: Using BALB/c mice sensitized to ovalbumin (OVA) and treated twice with either BCG or M. vaccae (1 x 105 CFU, intranasally), we investigated airway resistance of both the EAR and LAR, AHR to methacholine, serum total and antigen-specific IgE, cysteinyl leukotrienes in bronchoalveolar lavage (BAL) fluid (10 min following challenge), a complete cell differential of the BAL (24 h post-challenge), BAL and serum cytokines and lung histology. Results: Neither BCG nor M. vaccae were able to attenuate the EAR, yet both were able to abrogate the parameters used to evaluate the LAR. Interestingly, in neither case were serum or OVA-specific IgE levels reduced after treatment with mycobacterial antigens and type 1/type 2 T cell cytokine skewing, based on cytokine levels in BAL and serum, was incomplete. Conclusions: These results have led us to conclude that the mycobacterial antigens elicit potential anti-asthmatic effects independent of changes in IgE levels. We speculate that mycobacteria likely directly or indirectly suppress eosinophil effector function via attenuation of type 2 T cell-mediated immune responses.",
author = "Hopfenspirger, {Michael T.} and Parr, {Sharidan K.} and Townley, {Robert G.} and Agrawal, {Devendra K.}",
year = "2002",
doi = "10.1046/j.1440-1592.2002.00244.x",
language = "English",
volume = "51",
pages = "21--32",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "1",

}

TY - JOUR

T1 - Attenuation of allergic airway inflammation and associated pulmonary functions by mycobacterial antigens is independent of IgE in a mouse model of asthma

AU - Hopfenspirger, Michael T.

AU - Parr, Sharidan K.

AU - Townley, Robert G.

AU - Agrawal, Devendra K.

PY - 2002

Y1 - 2002

N2 - Background: Since the observation that Bacillus Calmette-Guérin (BCG) vaccination in children correlates with a decreased prevalence of asthma, several investigators have been attempting to reproduce this effect experimentally in mouse models of asthma. While these reports have agreed in some areas, uncertainty has remained as to the effect of BCG on IgE and asthmatic response in general. Furthermore, the effect of mycobacterial antigens on the early allergic response and the release of bronchoconstrictory mediators have not been examined. In the present study, we have aimed to more completely describe the effect of BCG and Mycobacterium vaccae on early and late allergic responses (EAR and LAR, respectively), airway hyperresponsiveness (AHR) and broncho-constrictory mediators in the mouse model of allergic airway inflammation. Methods: Using BALB/c mice sensitized to ovalbumin (OVA) and treated twice with either BCG or M. vaccae (1 x 105 CFU, intranasally), we investigated airway resistance of both the EAR and LAR, AHR to methacholine, serum total and antigen-specific IgE, cysteinyl leukotrienes in bronchoalveolar lavage (BAL) fluid (10 min following challenge), a complete cell differential of the BAL (24 h post-challenge), BAL and serum cytokines and lung histology. Results: Neither BCG nor M. vaccae were able to attenuate the EAR, yet both were able to abrogate the parameters used to evaluate the LAR. Interestingly, in neither case were serum or OVA-specific IgE levels reduced after treatment with mycobacterial antigens and type 1/type 2 T cell cytokine skewing, based on cytokine levels in BAL and serum, was incomplete. Conclusions: These results have led us to conclude that the mycobacterial antigens elicit potential anti-asthmatic effects independent of changes in IgE levels. We speculate that mycobacteria likely directly or indirectly suppress eosinophil effector function via attenuation of type 2 T cell-mediated immune responses.

AB - Background: Since the observation that Bacillus Calmette-Guérin (BCG) vaccination in children correlates with a decreased prevalence of asthma, several investigators have been attempting to reproduce this effect experimentally in mouse models of asthma. While these reports have agreed in some areas, uncertainty has remained as to the effect of BCG on IgE and asthmatic response in general. Furthermore, the effect of mycobacterial antigens on the early allergic response and the release of bronchoconstrictory mediators have not been examined. In the present study, we have aimed to more completely describe the effect of BCG and Mycobacterium vaccae on early and late allergic responses (EAR and LAR, respectively), airway hyperresponsiveness (AHR) and broncho-constrictory mediators in the mouse model of allergic airway inflammation. Methods: Using BALB/c mice sensitized to ovalbumin (OVA) and treated twice with either BCG or M. vaccae (1 x 105 CFU, intranasally), we investigated airway resistance of both the EAR and LAR, AHR to methacholine, serum total and antigen-specific IgE, cysteinyl leukotrienes in bronchoalveolar lavage (BAL) fluid (10 min following challenge), a complete cell differential of the BAL (24 h post-challenge), BAL and serum cytokines and lung histology. Results: Neither BCG nor M. vaccae were able to attenuate the EAR, yet both were able to abrogate the parameters used to evaluate the LAR. Interestingly, in neither case were serum or OVA-specific IgE levels reduced after treatment with mycobacterial antigens and type 1/type 2 T cell cytokine skewing, based on cytokine levels in BAL and serum, was incomplete. Conclusions: These results have led us to conclude that the mycobacterial antigens elicit potential anti-asthmatic effects independent of changes in IgE levels. We speculate that mycobacteria likely directly or indirectly suppress eosinophil effector function via attenuation of type 2 T cell-mediated immune responses.

UR - http://www.scopus.com/inward/record.url?scp=0036201289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036201289&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1592.2002.00244.x

DO - 10.1046/j.1440-1592.2002.00244.x

M3 - Article

AN - SCOPUS:0036201289

VL - 51

SP - 21

EP - 32

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 1

ER -